Background: The efflux transporter MRP1 actively transports antiretrovirals and reduces intracellular accumulation in peripheral blood mononuclear cells (PBMCs). We studied MRP1 expression and function in healthy volunteers treated with darunavir/ritonavir and efavirenz. Methods: Seven healthy HIV-negative volunteers were recruited. PBMCs were collected at baseline, 9 days after administration of darunavir (900 mg) and ritonavir (100 mg) once daily, 9 days after coadministration of darunavir/ritonavir and efavirenz (600 mg) once daily and 13 days after administration of efavirenz alone. In vitro studies have demonstrated that reverse transcriptase inhibitors down-regulate MRP1 and increase concentrations of some ARVs in cells [8] ; however, to our knowledge, the effects of ARV drugs on MRP1 have not been studied prospectively in clinical settings.
Most antiretroviral (ARV) therapies exert their therapeutic effects intracellularly and, in particular, in HIV-infected CD4 + T-cells. There is large intraindividual variability in intracellular concentrations of ARVs [1] , which could contribute to treatment failure and the development of resistance. Some of this variability is because of the activity of various efflux transporters found on CD4 + T-cells. The multidrug resistance-associated protein 1 (MRP1; ABCC1) is a member of the ATP-binding cassette (ABC) family that, together with P-glycoprotein (P-gp; ABCB1), actively pumps out multiple substrates across plasma membranes. MRP1 is found on CD4 + T-cells and is expressed at higher levels in HIV-infected patients [2] . Overexpression of MRP1 has been shown to reduce intracellular accumulation of various ARV drugs, including emtricitabine [3] , lopinavir [4] , saquinavir [5] , indinavir [6] and ritonavir [7] , and could contribute to treatment failure.
In vitro studies have demonstrated that reverse transcriptase inhibitors down-regulate MRP1 and increase concentrations of some ARVs in cells [8] ; however, to our knowledge, the effects of ARV drugs on MRP1 have not been studied prospectively in clinical settings.
We therefore studied the expression and function of MRP1 in healthy volunteers treated with two commonly 
Methods

Study group
Healthy men and women between 21 and 65 years of age were recruited for this open-label study. HIV-infected patients, patients with clinically significant medical conditions, smokers and those with a known history of alcohol and/or drug abuse were excluded from the study. Exclusion criteria also included allergies to any of the study drugs, hepatitis B and C infections, recent participation in an investigational drug study and inability to refrain from the use of prescription and non-prescription medications. Individuals agreed to participate in the study by giving written informed consent prior to study commencement. The study protocol was reviewed and approved by Domain Specific Review Board, National Healthcare Group. Written informed consent was obtained from all volunteers. The studies were conducted in accordance with the guidelines on good clinical practice and with the ethical standards for human experimentation established by the Declaration of Helsinki. Volunteers were given darunavir (900 mg) and ritonavir (100 mg) daily for the first 10 days. Efavirenz (600 mg once daily) was added for the next 14 days. Darunavir/ritonavir was then discontinued and only efavirenz (600 mg once daily) was given for the last 14 days of the study. A 10 ml sample of blood was taken on days 0 (baseline), 9 (after 9 days of darunavir/ ritonavir), 23 (after 9 days of darunavir/ritonavir with efavirenz) and 37 (after 13 days of efavirenz alone) for measurement of MRP1.
Measurements of MRP1
Fresh blood was layered on top of Ficoll-paque plus ® (GE Healthcare, Uppsala, Sweden) solution and centrifuged. Peripheral blood mononuclear cells (PBMCs) were isolated and washed twice with cold phosphatebuffered saline (PBS). After washing, PBMCs were transferred to cryotubes and cryopreserved in 90% fetal calf serum (FCS) and 10% dimethyl sulfoxide in liquid nitrogen. PBMCs were thawed when ready for analysis.
For the MRP1 protein expression assay [9] , cells were washed three times with PBS before staining with MRP1m6 antibody (Abcam, Cambridge, UK). Cells were treated with permeabilization reagent (Beckman Coulter, Marseille, France) for 5 min at room temperature according to the manufacturer's protocol. MRP1m6 antibody was added to sample tubes and isotypic control antibody added to control tubes. The cells were then incubated in the dark for 15 min. Cells were washed three times with PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibody (Abcam) in the dark for 15 min. Cells were washed three times with PBS before fluorescence measurement using flow cytometry (Cyan ADP; Dako Cytomation, Glostrup, Denmark). MRP1 expression was calculated as the fluorescence of MRP1 antibody after subtracting the fluorescence of the isotypic control.
To label CD4 + T-cells, 5×10 5 cells were incubated with CD4-phycoerythrin (Beckman Coulter) in the dark for 15 min. Fixation reagent was added and the mixture vortexed. Cells were then incubated for 15 min at room temperature before proceeding to the MRP1 assay above. MRP1 expression was measured directly in CD4 + T-cells by gating PBMCs stained with phycoerythrin.
For the MRP1 efflux assay [9] , PBMCs were washed and resuspended in RPMI 1640 (Gibco, Carlsbad, CA, USA). An aliquot containing 5×10
5 cells was incubated with 0.2 µM carboxyfluorescein (CFDA; Fluka, St. Louis, MO, USA) for 20 min at 37°C in the presence or absence of combined modulators 2 mM probenecid (Sigma-Aldrich, St. Louis, MO, USA) and 10 µM MK571 (Calbiochem, Darmstadt, Germany). At the end of the incubation, half of the cells were washed and sent for fluorescence analysis on flow cytometry with an FL1 detector; the other half were washed and resuspended in CFDA-free medium and allowed to efflux for 60 min at 37°C with or without modulators. After incubation, CFDA fluorescence was analysed using Cyan ADP flow cytometry (Dako Cytomation). Efflux effect was calculated as the ratio of median fluorescence with modulators divided by the median fluorescence without modulators.
MRP1 expression and function parameters were logtransformed prior to analysis. Paired t-tests were performed for the log-transformed data for days 9, 23 and 37 compared with baseline. Results were expressed as geometric mean ratios (GMR) with 95% confidence intervals (95% CIs) compared with baseline. Stata version 10 (StataCorp LP, College Station, TX, USA) was used for the statistical analyses.
Results
For this study, seven healthy volunteers were recruited: four males and three females. Ages ranged from 24 to 38 years. Weights ranged from 54 to 83 kg. All individuals developed mild to moderate neurological side effects from efavirenz. One individual developed grade 2 maculopapular rashes on the limbs and trunk on day 9 of darunavir/ritonavir treatment, which resolved after 16 days. One individual developed fever, abdominal pain, vomiting and transaminitis (aspartate aminotransferase/alanine aminotransferase >9× upper limit of normal) while taking efavirenz alone, which lasted 150 days after stopping. She also developed a grade 1 transient papular rash, as did two other female participants. These rashes occurred during the efavirenz alone part of the study.
After administration of darunavir and ritonavir, MRP1 protein expression in PBMCs was significantly and consistently reduced, with a GMR of 0.58 (95% CI 0.51-0.65; P<0.001; 
Discussion
We found that treatment with darunavir/ritonavir and efavirenz altered MRP1 expression and function in healthy volunteers. Darunavir/ritonavir significantly reduced MRP1 protein expression. This is consistent with in vitro studies showing that ritonavir and indinavir inhibit MRPs in PBMCs [10] . Various other ARVs have also been shown to inhibit MRP1, MRP2 and MRP3 [8] . Ritonavir and other protease inhibitors also inhibit P-gp in PBMCs [11] . Inhibition of both MRP1 and P-gp has previously been shown to increase intracellular concentrations of protease inhibitors [4, 7] . Thus, the inhibitory effect of darunavir/ritonavir on MRP1 might increase intracellular accumulation of ARVs. This could lead to beneficial intracellular interactions, which are not evident from measuring plasma concentrations alone, by increasing intracellular concentrations of other ARVs that are substrates of MRP1. Inhibition of MRP1 might also restore antiviral response, as failure to respond to ARVs is associated with up-regulation of MRP1 and other transporters [2] .
In addition, MRP1 might efflux other substances that interfere with HIV replication [10] . Inhibition of MRP1 could thus contribute to the antiviral activity of protease inhibitors through a mechanism independent of the ability of these drugs to inhibit the HIV protease.
We found that MRP1 protein expression was higher in CD4 + T-cells, both at baseline and after treatment. This finding is consistent with a previous study showing increased MRP1 mRNA in CD4 + T-cells [12] . This result is important because HIV preferentially infects CD4 + T-cells. Overexpression of MRP1 or other transporters on CD4 + T-cells might thus reduce ARV concentrations at their major site of action and inhibition of MRP1 could help to restore antiviral activity.
By contrast, we found that efavirenz increased MRP1 efflux function, but not protein expression. This finding is contrary to previous studies showing that efavirenz directly inhibits the function of MRP1 [8] . This finding could be explained by the fact that the efflux function assay is not as specific as the protein expression assay and could be measuring effects on other transporters [9] . In contrast to previous studies, we used both MK571 and probenecid as modulators in our efflux assay because using this combination of inhibitors correlated best with MRP1 activity. The correlation coefficient (r) of the MK571 and probenecid combination to MRP1 expression was 0.90, compared with 0.49 for MK571 alone and 0.65 for probenecid alone [13] . This might reduce the specificity of the assay, as other transporters could have been inhibited; for example, MK571 has been shown to inhibit P-gp (ABCB1), BCRP (ABCG2) and MRP2 (ABCC2) [14] , whereas probenecid is known to inhibit various human organic anion transporters [15] .
Efavirenz is known to induce various transporters in PBMCs [16] and our results support this; however, this result does raise concerns that efavirenz treatment might reduce intracellular concentrations of other ARVs and increase the probability of treatment failure.
When efavirenz was added to darunavir/ritonavir, the reduction of MRP1 expression by daunavir/ritonavir was attenuated slightly, but was still significantly reduced compared with baseline. MRP1 efflux function of this combination was even higher than with efavirenz alone. These results raise concerns about the possible reduction of intracellular concentrations of other ARVs with this combination. Studies on intracellular interactions between efavirenz and protease inhibitors would be required to confirm these findings.
Our study has several limitations. Firstly, we gave darunavir and ritonavir together, so we cannot isolate the effect of either agent alone on MRP1. However, information on either drug alone would be less clinically useful, as darunavir is always given together with ritonavir. Secondly, there was no washout period for efavirenz and it is possible that there were carry-over effects of darunavir/ritonavir on efavirenz; however, these effects are likely to be small after 14 days. Thirdly, we did not measure the activity of P-gp or other transporters. We chose to concentrate on MRP1 as much work has already been done on P-gp and because MRP1 is increasingly recognized as playing a major role in determining intracellular concentrations of ARVs. Finally, we did not measure intracellular ARV concentrations, although it is important to point out that intracellular measurement methods have practical difficulties and limitations [17] .
In conclusion, we found that darunavir/ritonavir and efavirenz exerted differential effects on the MRP1 transporter, as measured by different ex vivo assays in PBMCs from healthy volunteers. This could lead to changes in intracellular concentrations of ARVs with possible direct effects on HIV replication. Further clinical studies should consider measuring intracellular drug concentrations and transporter activity, so as not to miss these important interactions. Findings should be confirmed in HIV-positive patients.
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